Company outline

Head office: Kita 1-jo Nishi 3-chome 3-27,
Chuo-ku, Sapporo, 060-0001
Established: April 1, 2010
Paid in capital: 10,000,000 Japanese yen
Representative: Ichiro Ono (President)

Our mission

• Research on remedial effects of growth factors on suture wounds, scars, keloids and skin atrophy/aging due to ultraviolet ray damage and related clinical application.
• National and international patent applications based on the results of the above research, and retention of related rights.
• Pharmaceutical production in Japan and globally based on the results of the above research, and development of alliances with firms supporting the domestic and international distribution of pharmaceutical agents.
• Development and sales/sales tie-ups relating to medical equipment, quasi-pharmaceutical products and cosmetics based on growth factors for rejuvenation.
• Establishment and research of methods for regeneration of skin and skin appendages.

Proposal for microneedle system using an impact-insertion applicator to administer DNA plasmid vaccine for COVID-19

We have developed a microneedle system using an impact-insertion applicator to administer a DNA plasmid vaccine for COVID-19. While simple, this system is ideal for ensuring the vaccine is only administered to the upper dermis of the skin. We have improved and perfected this treatment strategy through more than ten years of clinical studies in which 20,000 patches were administered. Moreover, the system has been proven capable of delivering one hundred percent of the drug loaded to the tips of microneedles measuring 600 μm in length, which stimulate Langerhans cells in the epidermis to induce antigens with just a small amount of vaccine.

Introducing Breakthrough for Vaccine Transdermal Simple Injection System “Medical Micro Needle”.PDF

microneedle - SD 480p.mov